NewslettersDermal Cell News Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma By lbeveridge - August 29, 2022 0 Iovance Biotherapeutics, Inc., has initiated a rolling BLA submission to the US FDA for lifileucel, a tumor infiltrating lymphocyte therapy, in patients with advanced melanoma. [Iovance Biotherapeutics] Press Release